Saad Usmani: Daratumamab + Rd Versus Bortezomib-Containing Regimens
By Saad Z. Usmani, MD, MBA, FACP - Last Updated: November 14, 2022Saad Z. Usmani, MD, MBA, FACP, discusses an indirect treatment comparison study which assesses daratumumab plus lenalidomide and dexamethasone (D-Rd) and bortezomib-containing regimens in patients with newly diagnosed transplant-ineligible multiple myeloma.
Advertisement
Post Tags:MM
Advertisement
Related Posts
The approval is based on the DREAMM-7 and DREAMM-8 trials, in which belantamab mafodotin showed favorable survival benefit.
Experts call for rethinking smoldering myeloma as a distinct disease, with new data supporting early risk-based intervention.
Experts discuss the link between dietary patterns and blood cancer risk and the shortcomings of epidemiological studies.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
The agent is designed to be an option for cases where CAR T-cell therapies or first-generation bispecifics are unsuccessful.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.